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Abstract
Background: Western diet and lifestyle are associated with overweight, obesity, and type 2 diabetes, which, in turn,
are correlated with neuroinflammation processes. Exercise and a healthy diet are important in the prevention of these
disorders. However, molecules inhibiting neuroinflammation might also be efficacious in the prevention and/or
treatment of neurological disorders of inflammatory etiology. The abscisic acid (ABA) is a phytohormone involved in
hydric-stress responses. This compound is not only found in plants but also in other organisms, including mammals. In
rodents, ABA can play a beneficial role in the regulation of peripheral immune response and insulin action. Thus, we
hypothesized that chronic ABA administration might exert a protective effect in a model of neuroinflammation
induced by high-fat diet (HFD).
Methods: Male Wistar rats were fed with standard diet or HFD with or without ABA in the drinking water for 12 weeks.
Glucose tolerance test and behavioral paradigms were performed to evaluate the peripheral and central effects of
treatments. One-Way ANOVA was performed analyzed statistical differences between groups.
Results: The HFD induced insulin resistance peripherally and increased the levels of proinflammatory markers
in in the brain. We observed that ABA restored glucose tolerance in HFD-fed rats, as expected. In addition,
chronic ABA treatment rescued cognitive performance in these animals, while not affecting control diet fed
animals. Moreover, it counteracted the changes induced by HFD in the hypothalamus; microglia activations
and TNFα mRNA levels.
Conclusion: These results suggest that ABA might become a new therapeutic molecule improving the
neuroinflammatory status and insulin resistance.
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Background
Obesity, a leading cause of type 2 diabetes [1], correlates
with cognitive impairment. Insulin sensitizers have been
proposed as a promising tool for the reduction of
obesity-induced insulin resistance and inflammation
processes. The thiazolidinediones (TDZ) are a family of
synthetic insulin sensitizer molecules; however, some of
them have undesirable side effects [2–4]. Thus, alterna-
tive compounds with analogous properties but fewer
side effects are needed. The phytohormone abscisic acid
(ABA) was found in mammalian cells more than 25 years
ago [5]. Since then, several studies have proposed it as a
universal signaling molecule [6, 7]. Structurally, ABA is
very similar to the TDZs. Indeed, ABA can improve
glucose tolerance [8], reduce the level of TNFα, and
decrease adipocyte cell size in an in vivo model of obes-
ity induced by HFD [9]. Moreover, in human and murine
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pancreatic cell lines (RIN-m and INS-2 cells), ABA can
increase glucose-stimulated insulin secretion [10]. This
effect can be repressed using pertussis toxin and PKA
inhibitors [11]. Dietary ABA also stimulates granulocyte
function and macrophage infiltration in the adipose tis-
sue [12]. In mammalian cells, the lanthionine synthetase
C-like protein 2 (LANCL2) shows high homology with
the ABA receptor in plants, the Arabidopsis GCR2.
Silencing the expression of endogenous LANCL2 in
granulocyte cells can abrogate ABA induction of Ca2+
responses, whereas overexpression of LANCL2 enhances
the ABA-mediated effects [13]. Because of its role in the
mediation of ABA effects, LANCL-2 has been proposed
as a therapeutic target for the treatment of inflammatory
diseases and diabetes [14].
Furthermore, ABA shows some molecular structural
similarities to retinoic acid (RA). RA has beneficial cog-
nitive effects, rectifying memory deficits in rodent
models of Alzheimer disease. However, the clinical and
animal model data show an association between RA
administration and the symptoms of depression [15].
Chronic treatment with ABA has beneficial antidepres-
sant effects demonstrated by increased sucrose intake,
increased swimming in the forced swim test, and re-
duced expression of CRH and RARα mRNA in the rat
hypothalamus in control rats, with no reported side ef-
fects [16]. Moreover, preliminary data show an improved
spatial memory in rats treated with ABA [17]. On the
basis of these data, we hypothesized that as ABA can
modulate peripheral insulin resistance and immune re-
sponse, it might also exert similar action centrally. Thus,
it this work aims to show whether dietary ABA could re-
store cognitive deficits resulting from a high fat diet
(HFD) induced neuroinflammation. HFD elevates the
levels of neuroinflammation markers in the brain [18]
and it might constitute a link between obesity and
degenerative disorders via insulin resistance [19]. Fur-
thermore, HFD has been shown to induce memory loss
through elevation of inflammatory markers in hippo-
campus [20].
We administered ABA (20 mg/L) in the drinking water
to rats on either HFD or standard diet (SD). After eleven
weeks of treatment, we compared the behavior of the
four groups using two memory paradigms: the novel ob-
ject recognition (NOR) and the T-maze. In addition, we
measured ABA levels in the blood and cerebellum of all
four groups using HPLC. We analyzed the microglia
proliferation using immunohistochemistry. We demon-
strated that the ABA administered in drinking water im-
proved glucose tolerance and cognitive performance and
decreased the levels of inflammatory markers in the
hypothalamic areas. Our results confirm a therapeutic
potential of this phytohormone in the peripheral meta-
bolic alterations. The data also strongly suggest the
potential beneficial effects of ABA in disorders of neu-
roinflammatory etiology, which has not been demon-
strated before.
Methods
The aim of the experiment is to evaluate the central
effects of the phytohormone, ABA in a model of neuro-
inflammation elicited by HFD, during 12-week treat-
ment. Behavioral tests started on the 11th week, and
sacrifices were carried out in the 12th week of ABA and
diet treatment (Fig. 1).
Animals and diet
Eight-week-old male Wistar rats were obtained from the
Janvier Labs (Saint-Berthevin, France) and kept at the
animal facility of the University Jaume I. The procedures
followed the directive 86/609/EEC of the European
Community on the protection of animals used for ex-
perimental and other scientific purposes. The experi-
ments were approved by the Ethics Committee of the
University Jaume I. The animals were maintained on a
12 h:12 h light–dark cycle and housed in pairs to reduce
stress due to social isolation. Rats were divided randomly
into four experimental groups: SD, control animals fed the
standard rodent diet (Ssniff, Soest, Germany); SD-ABA,
animals fed standard diet supplemented with ABA
(Fernandez-Rapado, Spain) in the drinking water (20 mg/
L); HFD, animals fed a high-fat diet (5736 kcal/kg, Ssniff)
(Table 1); and HFD-ABA, animals fed high fat diet and
ABA in drinking water (20 mg/L). We based our estima-
tions in previous papers where ABA had been administered
in the food pellet. Considering the daily food (20 g/day) and
water average intake (50 mL/day), we estimated the amount
of ABA per mL of drinking water, in order to doses in the
same range as previous papers (100 mg/Kg) [21]. In Guri
study, the period of ABA treatment was shorter (36 days)
Fig. 1 Experiment design. Behavioral tests started in the 11th week, and the animals were sacrificed in the 11th and 12th week
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than our study (12 weeks), therefore we considered that the
ABA administration could be lowered (1 mg/day) to
achieve optimal chronic effects. The four groups were fed
ad libitum for 12 weeks. The HFD diet induces inflamma-
tory effects in the peripheral tissues [21] and the brain [22].
The body weight and food and water intake were moni-
tored twice a week per cage.
Novel object recognition (NOR)
Training chamber consisted of a black wooden box
(81 × 61 × 52.3 cm). Rats were habituated to the testing
environment for 30 min on two consecutive days. On
the first day, the rats spent a 10-min habituation period
in the experimental box, without objects. On the second
day, each rat was placed in the box for the familiarization
phase and allowed to explore two identical objects (heavy
metallic jars). One group (easy task group) was left for
10 min, and the second group (difficult task group) was
left to explore for 3 min. All the rats were then returned
to their home cages for a 1-h intertrial interval. The box
and objects were cleaned with a 30 % ethanol solution. In
the test phase, the rats were returned to the box and
allowed to explore a familiar and novel object for further
5 min (easy task group) or 3 min (difficult task group)
[23]. Familiar and novel objects were alternated between
left and right to prevent location predisposition. Both trial
and test phases were recorded using a video tracking
system (Smart 2.5.19, Panlab, Barcelona, Spain) for subse-
quent behavioral analysis. Exploration was defined as time
spent sniffing within 1–4 cm of the object or touching it,
always with the head oriented towards the object. Climb-
ing over the object or running around it was not consid-
ered exploration.
T-maze
The T-maze was a three-arm maze; one arm (119.3 ×
18.2 cm) was longer than the other two, which were
identical (21.1 × 34.5 cm); the entire maze was placed
above the floor. The longer arm was chosen as the start
arm. The rats were habituated to the behavior room for
30 min. On the test day, the animals were allowed to
explore the maze for 5 min, with access to two of the
three arms (the home or start arm and the familiar arm).
The rat was then returned to its home cage for a 2-h in-
tertrial interval (difficult task group) or 90-min intertrial
(easy task group), during which the maze was cleaned
with 30 % ethanol. The rat was then placed back in the
maze; this time the animal had access to all arms for
5 min [24]. The number of entries to the novel arm and
the time rat spent in each arm was recorded using a
video tracking system (Smart 2.5.19).
Glucose tolerance test
Rats were fasted overnight, and a drop of blood was
taken from the tail before (t = 0) and 30 min (t = 30) and
120 min (t = 120) after glucose administration (2 g/kg).
Plasma glucose was measured using Glucomen LX Plus
glucometer.
HPLC ABA measurements
ABA was analyzed in all four groups using LC/ESI-
MSMS, essentially as described in [25], with slight
modifications. Briefly, 1 g of frozen tissue was extracted
in ultrapure water using a tissue homogenizer (Ultra-
Turrax, Ika-Werke, Staufen, Germany) after spiking with
100 ng of d6-ABA. After extraction and centrifugation,
pH of the supernatant was adjusted to 3.0, and it was par-
titioned twice against diethyl-ether (Panreac, Barcelona,
Spain). The organic layers were combined and evaporated
in a centrifuge vacuum evaporator (Jouan, Saint-Herblain,
France). The dry residue was then resuspended in water–
methanol (9:1) solution, filtered and injected into a
UPLC™ Acquity system (Waters, Milford, MA, USA). The
analyte was then separated on a reversed phase UPLC
C18 column (Nucleodur C18, 1.8 μm, 50 × 2.0 mm,
Macherey-Nagel, Barcelona, Spain). The solvents were
methanol and water supplemented with 0.01 % acetic acid,
applied at a flow rate of 300 μL min−1. ABA was quanti-
fied with a Quattro LC triple quadrupole mass spectrom-
eter (Micromass, Waters, Manchester, UK) connected
online to the output of the column through an orthogonal
Z-spray electrospray ion source. Quantitation of this hor-
mone was achieved by external calibration with known
amounts of standards.
Immunocytochemistry (ICC)
Rats were anesthetized with an overdose of pentobarbital
(120 mg/kg Eutanax, Fatro, Barcelona, Spain) and trans-
cardially perfused with saline (0.9 %) followed by 4 %
paraformaldehyde (PFA) fixative in 0.1 M phosphate
buffer, pH 7.4. After the perfusion, the brains were re-
moved from the skulls and postfixed overnight at 4 °C in
PFA. Then, the brains were immersed in 30 % sucrose
for 48 h for cryoprotection. Sliding Microtome Leica
SM2010R (Leica Microsystems, Heidelberg, Germany)
Table 1 Composition of high fat diet
Crude Nutrients % Additives per kg
Crude protein 24.4 Vitamin A (IU) 15000
Crude fat 34.6 Vitamin D3 (IU) 1500
Crude fibre 6.0 Vitamin E (mg) 150
Crude ash 5.5 Vitamin K3 (mg) 20
Starch 0.1 Vitamin C (mg) 30
Sugar 9.4 Copper (mg) 12
Fat 60 kJ%
Energy 21.6 MJ (or kcal) ME/kg
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was used to obtain 40-μm-thick coronal frozen sections.
The brains were cut in rostrocaudal direction; six series
of slices were collected from each brain and stored at
−20 °C for analysis.
For Iba1 staining, we used a goat anti-Iba1 (Abcam,
Cambridge, UK). Briefly, free-floating sections were
rinsed twice in 0.05 M Tris-buffered saline (TBS,
pH 8.0) and once in TBS with 0.2 % Triton X-100, at
room temperature. Sections were incubated in 4 % nor-
mal donkey serum for 1 h to reduce nonspecific labeling.
Afterward, the sections were incubated in the primary
antibody solution diluted 1:500 in 0.01 M phosphate
buffered saline (PBS) containing 2 % normal donkey
serum, TBS with 0.2 % Triton X-100, and 2 % bovine
serum albumin for 24 h at room temperature. After
washing off the excess of the primary antibody, the
sections were incubated in biotinylated donkey anti-goat
secondary antibody (Jackson) (1:200 in TBS, 0.2 %
Triton X-100). Two hours later, the sections were
transferred to the avidin–biotin–horseradish peroxid-
ase complex solution (Standard Elite ABC kit, Vector
Laboratories Burlingame, CA USA) for 90 min, followed
by two rinses with TBS with 0.2 % Triton X-100, and two
more with 0.05 M Tris/HCl pH 8.0. Then, the sections
were processed in 0.05 M Tris/HCl pH 8.0 containing
3.125 mg of DAB and 2 μL of H2O2 for 15–20 min. The
reaction was stopped by adding an excess of 0.05 M Tris/
HCl pH 8.0, followed by several rinses in PBS. Finally, the
sections were mounted onto gelatin-coated slides, air-
dried, dehydrated in alcohol, cleared in xylene, and cover-
slipped with DPX mounting medium.
RNA extraction and RT-PCR
Total RNA was extracted from the hypothalamus (n = 4–6
per group) using RNeasy Lipid Tissue Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
protocol. The RNA samples were resuspended in 50 μL of
nuclease-free water. RNA concentration and quantifica-
tion of total RNA was performed using Thermo Scientific
NanoDrop 2000c, with the OD260/OD280. Genomic
DNA was removed using DNase I, RNase-free (Life Tech-
nologies, USA), for 30 min at 37 °C. The reaction was
stopped by addition of 1 μl of EDTA for 10 min at 65 °C.
The first strand cDNA was synthesized using the Prime-
Script™ RT Reagent Kit (Perfect Real Time) (Takara Bio
Inc., Shiga Japan). For each reaction, 1 μg of RNA was
used for reverse transcription, in a mixture of 4 μL of 5 ×
PrimeScript Buffer; 1 μl of PrimeScript RT, 1 μL of Oligo
dT Primer (50 μM), and 1 μL of random primer
(100 μM). Enzyme mix was adjusted to a final volume of
20 μL at room temperature. The mixture was incubated at
37 °C for 15 min and heated at 85 °C for 15 min to
terminate the reaction. The cDNA was subsequently
stored at −20 °C. RT-PCR was performed in a volume of
10 μL with 5 μL of Maxima SYBR Green/ROX qPCR
Master Mix (2X) (Applied Biosystems Life Technologies,
Carlsbad, CA, USA), 1 μL of primer and 1 μL of cDNA.
All PCR reactions were performed under the following
conditions: initial cycle at 98 °C for 10 min followed by
40 cycles at 98 °C for 10 s, 60 °C for 10 s, and 72 °C for
20s. Gene expression in the hypothalamus and hippocam-
pus was quantified using a StepOnePlus Real-Time PCR
system (Applied Biosystems Life Technologies). The RT-P
CR primers for TNFα were Forward 5′GACCCTCAC
ACTCAGATCATCTTCT3′ and reverse 5′TGCTACG
ACGTGGGCTACG3′. Each sample was tested in tripli-
cate. Data were analyzed using the comparative critical
threshold method, with the amount of target gene nor-
malized to the housekeeping gene ß-actin. Relative gene
expression was calculated using 2 -ΔΔCt relative to control.
Results
Animals were weighed, and water and food consumption
was monitored twice a week. Behavioral tests started on
the 11th week, and sacrifices were carried out in the 12th
week of ABA and diet treatment (Fig. 1). As expected,
overnutrition affected the body weight, but ABA admin-
istration did not affect the weight gain in either group.
The results are presented as the means ± SE (n = 16 per
group). Control animals fed SD increased their body
weight from 444 ± 11.7 g (week 1) to 585 ± 12.0 g (week
10). Similarly, animals on SD supplemented with ABA
increased their body weight from 446 ± 10.7 g (week 1)
to 593 ± 10.2 g (week 10). This represents an increment
of 132 ± 2.4 % and 133 ± 1.5 %, for SD and SD with
ABA, respectively. However, animals fed HFD and HFD-
ABA increased their body weight from 448 ± 11.7 and
453 ± 12.2 g (week 1) to 659 ± 16.0 and 669 ± 16.2 g
(week 10), an increase of 148 ± 3.2 % and 148 ± 2.8 %, re-
spectively (Fig. 2a). Data were analyzed using a two-way
ANOVA; time (F(10,600) = 994, p < 0.0001) and diet
(F(3,60) = 6.08, p = 0.001) had a significant effect. Food
and water consumption was measured per cage. Food
intake data is represented by the mean (g) of food con-
sumed ± SE per cage each week (n = 8 per group).
Weekly consumption was steady during the 12 weeks
treatment, but the diet clearly affected food intake. The
data were analyzed using two-way ANOVA (F(3,28) = 75.36
p < 0.0001). To determine the ABA intake, we monitored
weekly water consumption (Fig. 2c). Based on this infor-
mation, we calculated ABA intake for both HFD and SD
fed animals, and confirmed that both groups had a similar
average weekly intake of the hormone, 12.30 ± 1.4 and
13.27 ± 0.8 mg/week/cage, respectively (Fig. 2d).
It has been reported that dietary ABA given in the
food pellets (100 mg/kg food) can improve glucose toler-
ance [21]. To confirm that, in our model, ABA (20 mg/L
of drinking water) improved the glucose homeostasis,
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we performed a glucose tolerance test by intraperitoneal
injection of glucose (2 mg/kg) in fasted animals. After
11 weeks of treatment, the animals fasted overnight
(12–13 h). The basal glucose levels were similar in all
groups; 30 min after glucose injection, blood glucose
levels increased. No significant differences were ob-
served between the groups. However, two hours after
injection, glucose levels in HFD group remained higher
(235.4 ± 36 mg/dL) than in HFD-ABA group (158.9 ±
11.23 mg/dL). In the latter group, the glucose levels
were similar to those in control groups, SD (143.9 ±
10.24 mg/dL) and SD-ABA (152.6 ± 15.52 mg/dL).
The data were analyzed using one-way ANOVA, with
Newman–Keuls post-hoc test (p < 0.05) (Fig. 3).
HFD can induce memory impairments in rodents [26]
and humans [27]. To examine the effect of chronic ABA
administration on cognitive performance, the animals
were subjected to two behavioral paradigms that evalu-
ate the memory in rodents, NOR and T-maze test. NOR
exploits the innate exploratory preference of novel ob-
jects exhibited by rodents. This paradigm examines the
capability of the animal to remember a familiar object
when presented with a new one. We observed no signifi-
cant differences in the time spent exploring the identical
objects during familiarization phase (Fig. 4a and c).
During the test, all four groups spent much more time
exploring the novel object than the familiar one, and
neither the diet nor ABA treatment changed these pa-
rameters (Fig. 4b). However, we observed differences
when both the familiarization time and test time were
reduced to 3 min. In the HFD group, the times for
familiar and novel object did not differ significantly, sug-
gesting impairment in remembering the familiar object.
HFD-ABA animals behaved in the same way as the con-
trol groups (SD and SD-ABA), indicating that ABA
could abrogate the HFD-induced impairment (Fig. 4d).
In the T-maze test, we recorded the number of entries
to both maze arms, one of which was familiar and the
other was novel because it had been closed during the
habituation. We observed that rats fed SD, SD-ABA, and
HFD-ABA had a significantly higher number of entries
to the novel arm than to the familiar one. This was not
the case for the animals fed HFD only, suggesting that this
diet might impair the memory of the familiar arm (Fig. 5a).
The data were analyzed using unpaired Student’s t-test,
comparing familiar and novel arm; *p < 0.05 < **p < 0.01.
Interestingly, when the test was performed with a longer
inter-trial time between familiarization and test phases,
which may be a more difficult working memory task,
HFD-ABA did not rescue the alternation behavior shown
by the HFD group. We found that the difference between
the number of entries to the two arms was no longer sig-
nificant for HFD-ABA animals, in similarity with HFD
group. Both SD and SD-ABA group maintained a signifi-
cant difference in the exploratory behavior, entering the
novel arm more often (Fig. 5b).
ABA levels in the blood and brain (cerebellum) were
measured using HPLC. We detected variable amounts of
circulating ABA in treated animals. However, we were
unable to detect ABA under the same conditions in
untreated animals, confirming that we, indeed, were
observing exogenous ABA (Table 2). It has been
Fig. 2 Body weight in grams (a), food intake (b), water intake (c) and ABA weekly comsumption per cage (d) of rats fed high-fat diet (HFD, white
circles); HFD with ABA (HFD-ABA, black circles); standard diet (SD, white triangles), and SD-ABA (black triangles) for 10–11 weeks; n = 16 per group.
Values are mean ± SEM. #, p < 0.05; ##, p < 0.01 for HFD vs. SD. *, p < 0.05; **, p < 0.01, ***, p < 0.001 for HFD-ABA vs. SD
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reported that after intraperitoneal injections, ABA is
widely distributed in the brain [17]. To ascertain that
ABA crosses the blood–brain barrier in our model, we
measured the ABA levels in the cerebellum as a sentinel.
In similarity with the serum examination, ABA was only
detected in the brains of treated animals (Table 2). Inter-
estingly, only a very small proportion of circulating ABA
crosses the blood–brain barrier. Thus, we confirmed
that our method of ABA administration in drinking
water was appropriate for measuring potential peripheral
effects; the compound could cross the brain–blood
barrier and might be responsible for the observed behav-
ioral changes.
Next, we measured the levels of inflammatory markers
in the brain. We used immunohistochemistry to detect
the microglia-specific cytoplasmic marker Iba1 [28] in the
hypothalamus (Fig. 6a). We observed that the number of
microglial cells increased significantly in rat hypothalamus
of HFD-fed rats (1613 ± 260.5 cells/mm2) in comparison
with SD-fed controls (754 ± 135.2 cells/mm2). The ABA
treatment reduced this effect in HFD animals (888 ± 158.8
cells/mm2) but did not affect SD-fed animals (794 ± 178.4
Fig. 3 The effect of dietary ABA (20 mg/L drinking water) on blood
glucose levels in response to intraperitoneal (IP) glucose tolerance
test. After 12 weeks of treatment, animals from the four groups were
fasted overnight (12–13 h) and given 2 mg/kg of glucose by IP
injection. Blood drops were taken from the tail, and plasma glucose
concentration measured at the indicated times. Data are presented
as the mean ± SEM. White circles represent rats fed HFD; black
circles, HFD-ABA; white triangles, SD; and black triangles, SD-ABA.
Data points at 120 min were analyzed using one-way ANOVA
followed by post-hoc Newman–Keuls test. *, p < 0.05
Fig. 4 Behavioral data for rats on a standard diet (horizontal lines, SD), high-fat diet (white columns, HFD), and supplemented with ABA in
drinking water (20 mg/mL), HFD-ABA (diagonal lines) and SD-ABA (black columns) (n = 8). Novel Object Recognition data: time exploring two
similar objects during familiarization phase (a, c) and time exploring familiar and novel object during test phase (b, d). Data is presented as mean
± SEM and analyzed using paired Student t-test, familiar vs. novel. **p < 0.01; *** p < 0.001; ns, non-significant
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cells/mm2) (Fig. 6b; one-way ANOVA, p = 0.0135). Repre-
sentative images of microglia in the hypothalamus are
shown in Fig. 6 (HFD, Fig. 6c; HFD-ABA, Fig. 6d;
SD, Fig. 6e; and SD-ABA, Fig. 6f ). In HFD group,
apart from the increase in the number of Iba1-
positive cells, the microglia cells were less ramified
and more amoeboid than in controls, indicating an
activated state (insets in images).
Next, we examined the levels of inflammatory and
anti-inflammatory cytokines in the hypothalamus. The
hypothalamus was dissected from all groups, and total
RNA was isolated. Quantitative PCR was carried out to
determine the expression levels of different cytokines.
We observed that TNF-α levels increased in the hypo-
thalamus of HFD-fed rats in comparison with controls,
confirming the existing reports [29, 30]. ABA adminis-
tration restored TNFα levels to control values (Fig. 7).
On the other hand, we found no significant differences
in hippocampus, under the same conditions in all four
groups (data not shown).
Discussion
Excessive energy intake is a major cause of obesity,
which is recognized as one of the greatest threats to hu-
man health in the Western societies. Malfunction of
hypothalamic neurons appears to underlie the pathology
of metabolic diseases [31]. Even though the relationship
between obesity (excess body fat) and neurodegeneration
is highly complex, many sources link obesity and high
fat consumption with certain neurodegenerative pro-
cesses [19]. Growing evidence demonstrates that HFD
induces insulin resistance, immunological and synaptic
alterations in different brain areas [32, 33], and cognitive
impairment [34].
In animal obesity models, the phytohormone ABA,
related structurally to insulin sensitizers (TDZs) and
memory-improvement molecules (such as retinoic acid),
ameliorates the symptoms of type 2 diabetes. It targets
PPAR-γ in a manner similar to the TDZ class of antidia-
betic drugs [21, 35]. In this study, we demonstrate, for
the first time, that ABA can counteract some of the
neurological effects (cognitive impairment and neuroin-
flammation markers) induced by HFD. We, in this study,
and others have found that ABA can cross the blood
brain barrier, but whether the improvement on cognitive
functions is caused by direct action of ABA in brain,
remains elusive.
Our protocol was designed to avoid an increase in be-
havioral anxiety. ABA was administered in the drinking
water (20 mg/L) and not in food pellets since rats fed on
an HFD tend to eat less than controls [36]. The dose
was based on previous studies reporting dietary adminis-
tration of ABA [21]. The vehicle used to dissolve ABA
was added to water for SD and HFD groups to match
any possible taste alterations. Some studies have used
intraperitoneal injections (IP), which guarantee exact
Fig. 5 Behavioral data for rats on a standard diet (horizontal lines,
SD), high-fat diet (white columns, HFD), and supplemented with
ABA in drinking water (20 mg/mL), HFD-ABA (diagonal lines) and
SD-ABA (black columns) (n = 8). T-maze data: number of entries to
novel and familiar arm after 90 min intertrial interval (a) and number
of entries to novel and familiar arm after 2 h intertrial interval (b).
Data is presented as mean ± SEM (n = 8) and analyzed using paired
Student t-test, familiar vs. novel. *p < 0.05; **p < 0.01; *** p < 0.001;
ns, non-significant
Table 2 ABA quantification by HPLC. Cerebellum (A) and blood (B) were extracted from all four groups of treated animals
Cerebellum Serum
Diet group ABA detected (ng/gr tissue) Diet group ABA detected (ng/gr plasma)
HFD N.D HFD N.D
HFD-ABA 1.510 ± 0.030 HFD-ABA 196.8 ± 82.57
SD N.D SD N.D
SD-ABA 2.980 ± 0.100 SD-ABA 47.95 ± 13.80
ND not detected
ABA was only detected in animals that had received exogenous administration of ABA in the drinking water (20 mg/L)
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dosing but are highly anxiogenic. Another innovation in
our study was housing the animals in pairs to reduce
stress due to isolation [37]. We considered these issues
important since stress can affect feeding and cognitive
behavior in many indirect ways [38]. Therefore, reducing
the stress levels (by avoiding isolation and daily injec-
tions) was desirable. To examine the intake of ABA, we
examined the average weekly water consumption in
groups SD-ABA and HFD-ABA. Daily ABA intake was
approximately 1.5–1.8 mg/kg. During the 12-week
period, the intake average was uniform in all groups. To
validate our strategy as an effective way of drug adminis-
tration, we carried out a glucose tolerance test in all four
groups. We confirmed that ABA improves glucose toler-
ance, reducing blood glucose levels to the normogly-
cemic range two hours after glucose injection.
The effect of specific diets on cognitive performance in
rodents has been investigated using different behavioral
Fig. 6 Within the hypothalamus, ABA curtails the increase in microglia staining induced by high-fat diet (HFD). Map showing the location of the
analyzed hypothalamus (a). Anterior (bregma −1.80 mm) and medial (bregma −3.12 mm) hypothalamus were used for quantification (b). HFD fed
rats (c); HFD-ABA (d); standard diet, SD (e); and SD-ABA (f). Calibration bar, 200 μm (c–f). Data is represented as the mean ± SEM of density of cells
per mm2 (n = 6). Data were analyzed using one-way ANOVA followed by post hoc Newman–Keuls test; *, p < 0.05 vs. HFD. The reactive microglia
are shown in the insets at high magnification. Calibration bar, 50 μm
Fig. 7 Cytokine mRNAs levels in the hypothalamus: proinflammatory
cytokine TNFα in rats fed high fat diet (HFD, white columns); HFD
supplemented with ABA in drinking water (20 mg/L) (HFD-ABA, diagonal
lines); standard diet (SD, horizontal lines); and SD supplemented with
ABA (SD-ABA, black columns). Data are presented as mean ± SEM (n= 4–
6 rats) and analyzed using one-way ANOVA followed by Newman–Keuls
Multiple Comparison Test; *, p< 0.05 vs. HFD
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paradigms. Diets with increased sugar and fat content
cause impairment in spatial and working memory [39–41]
in both rats and mice. The link between obesity and in-
flammation of central nervous system is widely accepted;
the hypothalamus is the area where inflammatory markers
are most evident. Neuroinflammation underlies cognitive
impairment [1]. However, some reports have suggested
that ABA improves spatial memory [16]. ABA has anti-
inflammatory and insulin-sensitizing properties, and there
is some evidence suggesting that ABA is a PPARγ agonist
[42, 43]. Some reports have shown that PPARγ agonism in
the central nervous system ameliorates cognitive function
[44, 45]. Therefore, we hypothesized that ABA would alle-
viate the HFD-induced neuroinflammation and cognitive
defects. To follow up this assumption, we examined the
performance of the rats in two simple memory tests, NOR
and T-maze. In contrast to other reports, ABA did not
significantly affect the animals fed a control diet. This dis-
crepancy might have been caused by differences in animal
handling. As mentioned above, we housed the animals in
pairs to reduce the isolation anxiety and ABA was admin-
istered in the drinking water, reducing the IP injection-
induced stress. Under these conditions, the reduced
anxiety levels might have a positive effect on test perform-
ance. In the studies showing antidepressant-like effects of
ABA, the compound has been administered daily using an
IP injection [17]. We believe that in our model, the effect
of ABA is independent of its antidepressant activity.
In an NOR working-memory test, all groups, including
the HFD group, were able to discriminate between the
novel and the familiar object. However, when the time
spent in familiarization and test phases was shortened,
thus reducing/hurting the acquisition phase, HFD-fed ani-
mals spent similar time exploring the novel and the famil-
iar object. This indicated that they no longer remembered
the familiar object. This behavior was efficiently counter-
acted by ABA treatment. ABA-treated animals behaved
like the members of other groups, spending significantly
more time exploring the novel object.
The alternation test (the T-maze test) is considered a
reliable test to evaluate spatial working memory in ro-
dents [46, 47]. Using this paradigm, we found that HFD
could impair alternation; the animals had difficulties in
remembering the previously visited arms. Chronic treat-
ment with ABA can restore this capability. However,
when the intervals between the tests were increased,
making the task harder, HFD-ABA-fed animals no lon-
ger alternated, behaving like the animals in the HFD
group. This indicated that they had lost the ability to
discriminate between the familiar and novel arms. We
would not attribute these differences to ABA metabol-
ism, not only ABA is administered chronically, but
during the intertrial interval rats have access to water
and food. The peripheral anti-inflammatory effects ABA
are well known. However, to the best of our knowledge,
there is no data on the effect of ABA on the cerebral im-
mune response in vivo. Moreover, in vitro data are con-
troversial; some studies show that ABA activates the
microglia [48], whereas others report no effect [49].
Among the different types of glia, the resident macro-
phages in the brain, microglia, are responsible for cell
debris clearance and release of cytokines that recruit other
immunoresponsive cells to the central nervous system
[50]. In the metabolic syndrome induced by HFD, micro-
glia in the hypothalamus adopt a proinflammatory state,
which is linked to an abnormal increase in the production
of proinflammatory cytokines. These might be toxic to the
neurons [51, 52]. In this study, we investigated the micro-
glial expression in the hypothalamus in the four study
groups. We examined the immunoreactivity of ionized
calcium-binding adaptor molecule 1 (Iba1-ir), a cell
marker upregulated during microglial activation [28]. In
contrast to other studies of ABA effect on microglia in
vitro, reporting either activation [46] or no effect [49], we
demonstrated that in vivo, ABA reduces the number of
Iba1-positive cells. This finding suggests an important
practical application; the microglia hyperactivation has
been found in a number of alterations including traumatic
brain injury [53], cerebrovascular accidents [54], neurode-
generative disorders [55, 56], epilepsy [57], schizophrenia
[58], and depression [59]. In addition, we analyzed Iba-1
expression in dorsal hippocampus, but, HFD did not
increase microglia proliferation compared to control
groups (data not shown).
Further to test the anti-inflammatory effects of ABA in
the central nervous system, we measured the hypothal-
amic and hippocampal cytokine levels. The activated
microglia synthesize and secrete proinflammatory cyto-
kines, such as TNFα [60]. We observed an increase in
TNFα levels in the hypothalamus of HFD-fed rats. ABA
treatment rescued this effect, lowering TNFα to control
levels. Contrary to other studies where inflammation
markers have been found to increase in hippocampus,
we found no significant difference in inflammatory
markers TNF-α with HFD treatment compared to con-
trol groups. We postulate that not only hippocampal
neuroinflammation underlies cognitive impairments.
Conclusion
In summary, we found that chronic treatment with ABA
reduced HFD-induced microglia activation in hypothal-
amus, as revealed by Iba-1 staining. Also, TNF-α levels
were altered in hypothalamus of HFD-fed animals, and
these changes were counteracted by ABA administra-
tion. Moreover, ABA ameliorated the HFD-induced
impairments in cognitive performance. We found no
changes in neuroinflammatory markers in hypothalamus.
In this study, we show that hypothalamic inflammation can
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correlate with mild alterations in cognitive performance. Fi-
nally, based on our results, we conclude that ABA has a
protective effect in neuroinflammation conditions, lowering
microglia and TNFα levels and restoring cognitive function.
Given the fact that ABA can cross the blood brain barrier;
we postulate that this molecule could have a potential
therapeutic value in the treatment of diseases of neuro-
inflammatory etiology.
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